346 related articles for article (PubMed ID: 26976481)
1. Computer modeling of airway deposition distribution of Foster(®) NEXThaler(®) and Seretide(®) Diskus(®) dry powder combination drugs.
Jókay Á; Farkas Á; Füri P; Horváth A; Tomisa G; Balásházy I
Eur J Pharm Sci; 2016 Jun; 88():210-8. PubMed ID: 26976481
[TBL] [Abstract][Full Text] [Related]
2. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers.
Buttini F; Brambilla G; Copelli D; Sisti V; Balducci AG; Bettini R; Pasquali I
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):167-78. PubMed ID: 26355743
[TBL] [Abstract][Full Text] [Related]
3. Experimental and computational study of the effect of breath-actuated mechanism built in the NEXThaler
Farkas Á; Lewis D; Church T; Tweedie A; Mason F; Haddrell AE; Reid JP; Horváth A; Balásházy I
Int J Pharm; 2017 Nov; 533(1):225-235. PubMed ID: 28941830
[TBL] [Abstract][Full Text] [Related]
4. Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort(®) Turbuhaler(®) dry powder fixed combination aerosol drug.
Farkas Á; Jókay Á; Balásházy I; Füri P; Müller V; Tomisa G; Horváth A
Eur J Pharm Sci; 2016 Oct; 93():371-9. PubMed ID: 27552906
[TBL] [Abstract][Full Text] [Related]
5. Probing the particulate microstructure of the aerodynamic particle size distribution of dry powder inhaler combination products.
Jetzer MW; Morrical BD; Schneider M; Edge S; Imanidis G
Int J Pharm; 2018 Mar; 538(1-2):30-39. PubMed ID: 29289516
[TBL] [Abstract][Full Text] [Related]
6. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
[TBL] [Abstract][Full Text] [Related]
7. Can 'extrafine' dry powder aerosols improve lung deposition?
de Boer AH; Gjaltema D; Hagedoorn P; Frijlink HW
Eur J Pharm Biopharm; 2015 Oct; 96():143-51. PubMed ID: 26220014
[TBL] [Abstract][Full Text] [Related]
8. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
Kolanjiyil AV; Kleinstreuer C; Sadikot RT
Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
[TBL] [Abstract][Full Text] [Related]
9. The effect of exhalation before the inhalation of dry powder aerosol drugs on the breathing parameters, emitted doses and aerosol size distributions.
Farkas Á; Tomisa G; Kugler S; Nagy A; Vaskó A; Kis E; Szénási G; Gálffy G; Horváth A
Int J Pharm X; 2023 Dec; 5():100167. PubMed ID: 36824288
[TBL] [Abstract][Full Text] [Related]
10. The clinical relevance of dry powder inhaler performance for drug delivery.
Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
[TBL] [Abstract][Full Text] [Related]
11. Current Inhalers Deliver Very Small Doses to the Lower Tracheobronchial Airways: Assessment of Healthy and Constricted Lungs.
Walenga RL; Longest PW
J Pharm Sci; 2016 Jan; 105(1):147-59. PubMed ID: 26852850
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial.
Jõgi R; Lähelmä S; Vahteristo M; Happonen A; Haikarainen J
J Aerosol Med Pulm Drug Deliv; 2019 Apr; 32(2):88-98. PubMed ID: 30300557
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
14. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics.
Tarsin WY; Pearson SB; Assi KH; Chrystyn H
Int J Pharm; 2006 Jun; 316(1-2):131-7. PubMed ID: 16584855
[TBL] [Abstract][Full Text] [Related]
15. An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions.
Borgström L; Asking L; Lipniunas P
J Aerosol Med; 2005; 18(3):304-10. PubMed ID: 16181005
[TBL] [Abstract][Full Text] [Related]
16. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial.
Kanniess F; Scuri M; Vezzoli S; Francisco C; Petruzzelli S
Pulm Pharmacol Ther; 2015 Feb; 30():121-7. PubMed ID: 25088067
[TBL] [Abstract][Full Text] [Related]
17. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
Lipworth BJ; Clark DJ
Pulm Pharmacol Ther; 1997 Aug; 10(4):211-4. PubMed ID: 9695144
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
[TBL] [Abstract][Full Text] [Related]
19. Application of a One-Dimensional Computational Model for the Prediction of Deposition from a Dry Powder Inhaler.
Gourgoulianis K; Daniil Z; Athanasiou K; Rozou S; Bontozoglou V
J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):435-443. PubMed ID: 28683222
[TBL] [Abstract][Full Text] [Related]
20. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling.
Vulović A; Šušteršič T; Cvijić S; Ibrić S; Filipović N
Eur J Pharm Sci; 2018 Feb; 113():171-184. PubMed ID: 29054499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
